Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACADIA Pharmaceuticals's change in working capital for the quarter that ended in Jun. 2026 was MXN689 Mil.
ACADIA Pharmaceuticals's change in working capital for the fiscal year that ended in Dec. 2025 was MXN-1,616 Mil.
It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).
ACADIA Pharmaceuticals Change In Working Capital Related Terms
ACADIA Pharmaceuticals Change In Working Capital Historical Data
* Premium members only.
The historical data trend for ACADIA Pharmaceuticals's Change In Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals Change In Working Capital Chart
ACADIA Pharmaceuticals Change In Working Capital Calculation
Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-886 Mil.
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.
Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net
(566)
(614)
(796)
Inventories
(1,667)
(2,759)
(3,727)
Accounts payable
531
1,061
2,687
Accrued liabilities
103
271
(935)
Accrued income taxes
(1,224)
981
994
For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Working Capital of MXN-886 Mil mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Change In Working Capital of MXN-886 Mil as of Jun. 2026. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for ACADIA Pharmaceuticals.
Is ACADIA Pharmaceuticals' Change In Working Capital too high?
ACADIA Pharmaceuticals' current Change In Working Capital is MXN-886 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Change In Working Capital compare to LEGN and TNGX?
ACADIA Pharmaceuticals' Change In Working Capital of MXN-886 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Working Capital for a Biotechnology company?
A good Change In Working Capital depends on the Biotechnology industry context. However, Change In Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Working Capital mean?
A high Change In Working Capital can signal that a stock is expensive relative to its fundamentals. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals's current Change In Working Capital is MXN-886 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN353.99, compared to a current price of MXN499.00 — trading 41% above its estimated fair value. The current Change In Working Capital is MXN-886 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 75/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Working Capital calculated?
Change In Working Capital is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Change In Working Capital is MXN-886 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN499.00 is trading 41% above its estimated GF Value™ of MXN353.99.
GuruFocus considers ACADIA Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEX:ACAD:
Change In Working Capital: MXN-886 Mil
GF Value™: MXN353.99 vs. price of MXN499.00 (41% above fair value)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
75GF Score
Get the complete analysis for MEX:ACAD
Change In Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
